



PUBLICATION OF A TRANSPARENCY NOTIFICATION RECEIVED BY MITHRA PHARMACEUTICALS SA/NV

Liège, Belgium 09 January 2017 – Regulated information – In accordance with article 14 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA/NV publishes the following information:

Mithra Pharmaceuticals SA/NV has received a transparency notification dated 29 December 2016, which states that Bart Versluys (Versluys Invest BVBA, Versluys Bouwgroep BVBA), as a result of the net purchase of shares, now has 3,28% of the voting rights in Mithra Pharmaceuticals SA/NV (total number of voting rights : 31.129.756) and as a consequence, crossed the reporting threshold of 3%.

The detailed transparency notifications are available on the [Investors website](http://investors.mithra.com) of Mithra Pharmaceuticals SA/NV (investors.mithra.com).

An updated overview of the Mithra Pharmaceuticals SA/NV large shareholdings will be included in the corporate governance charter of Mithra Pharmaceuticals SA/NV, which will be made available on its website.

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer
+32 4 349 28 22 / +32 475 86 41 75
press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22
investorrelations@mithra.com

Consilium Strategic Communications

Jonathan Birt, Sue Stuart, Hendrik Thys
mithra@consilium-comms.com
+44 2 037 095 700

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.

Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com